Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.

BACKGROUND Li-Fraumeni syndrome (LFS) is a high-risk cancer predisposition syndrome caused by pathogenic germline variants of TP53. Cancer surveillance has noted a significant survival advantage in individuals with LFS; however, little is known about the feasibility, acceptance, and psychosocial effects of such a program. METHODS Pathogenic TP53 germline variant carriers completed a 7-part questionnaire evaluating sociodemographics, cancer history, surveillance participation, reasons for nonadherence, worries, and distress adapted from the Cancer Worry Scale. Counselees' common concerns and suggestions were assessed in MAXQDA Analytics Pro 12. RESULTS Forty-nine participants (46 females and 3 males), aged 40.0 ± 12.6 years, formed the study population; 43 (88%) had a personal cancer history (including multiple cancers in 10 [20%]). Forty-three individuals participated (88%) in surveillance during the study or formerly. Willingness to undergo surveillance was influenced by satisfaction with genetic testing and counseling (P = .019 [Fisher-Yates test]) but not by sociodemographics, cancer history, or distress level. Almost one-third of the participants reported logistical difficulties in implementing surveillance because of the high frequency of medical visits, scheduling difficulties, and the travel distance to their surveillance providers. Self-reported distress and perceived emotional burden for family members and partners were moderate (median for self-reported distress, 3.3; median for perceived emotional burden, 3.0). For both, the interquartile range was moderate to very high (2.7-3.7 and 3.0-3.7, respectively). CONCLUSIONS Individuals with LFS require efficient counseling as well as an accessible, well-organized, interdisciplinary, standardized surveillance program to increase adherence and psychological coping.

[1]  R. Whitehouse,et al.  Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY) , 2019, Journal of Medical Genetics.

[2]  M. Greene,et al.  Family Health Leaders: Lessons on Living with Li-Fraumeni Syndrome across Generations. , 2019, Family process.

[3]  M. Greene,et al.  Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence , 2019, Journal of psychosocial oncology.

[4]  E. Bleiker,et al.  Genetic counselling of young women with breast cancer for Li–Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals , 2018, Familial Cancer.

[5]  Nina Ditsch,et al.  Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer , 2018, Cancer medicine.

[6]  Parijatham S. Thomas,et al.  Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic , 2018, Familial Cancer.

[7]  D. Bluemke,et al.  Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort , 2017, JAMA oncology.

[8]  David M. Thomas,et al.  Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging , 2017, JAMA oncology.

[9]  David M. Thomas,et al.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis , 2017, JAMA oncology.

[10]  K. Rhiem,et al.  Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse , 2017, Geburtshilfe und Frauenheilkunde.

[11]  L. Strong,et al.  Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome , 2017, Clinical Cancer Research.

[12]  M. Golatta,et al.  Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics , 2017, Archives of Gynecology and Obstetrics.

[13]  R. Eeles,et al.  Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? , 2017, Familial Cancer.

[14]  P. Rosenberg,et al.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort , 2016, Cancer.

[15]  C. Moore,et al.  Psychometric properties of the Parenting Concerns Questionnaire in cancer survivors with minor and young adult children , 2016, Psycho-oncology.

[16]  J. Schiffman,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. , 2016, The Lancet. Oncology.

[17]  M. Golatta,et al.  Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer , 2016, Archives of Gynecology and Obstetrics.

[18]  M. Golatta,et al.  Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany , 2016, Breast Cancer Research and Treatment.

[19]  C. Bonaïti‐pellié,et al.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[21]  Udo Kuckartz,et al.  Qualitative Text Analysis: A Guide to Methods, Practice & Using Software , 2013 .

[22]  H. Vasen,et al.  Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?--A systematic review. , 2012, Critical reviews in oncology/hematology.

[23]  N. Aaronson,et al.  Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits , 2010, Familial Cancer.

[24]  N. Aaronson,et al.  Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Gebert,et al.  Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members , 2008, Clinical genetics.

[26]  Salma K. Marani,et al.  Psychological functioning in persons considering genetic counseling and testing for Li–Fraumeni syndrome , 2006, Psycho-oncology.

[27]  S. Shete,et al.  Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. , 2006, Cancer research.

[28]  J. Klijn,et al.  Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[30]  T. Lehnert,et al.  Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. Chompret,et al.  The Psychological Burden Inflicted By Multiple Cancers in Li-Fraumeni Families: Five Case Studies , 2001, Journal of Genetic Counseling.

[32]  Shih-Jen Hwang,et al.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. , 2003, American journal of human genetics.

[33]  A. Howell,et al.  Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer , 2001, Journal of medical genetics.

[34]  J. Garber,et al.  Li-Fraumeni Syndrome , 2001 .

[35]  C. Bonaïti‐pellié,et al.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals , 2000, British Journal of Cancer.

[36]  Salma K. Marani,et al.  Intention to learn results of genetic testing for hereditary colon cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  D. Miglioretti,et al.  Attitudes toward colon cancer gene testing: factors predicting test uptake. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  D. Wellisch,et al.  Daughters of Breast Cancer Patients , 1998 .

[39]  M. Stefanek,et al.  Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior. , 1994, Journal of the National Cancer Institute. Monographs.

[40]  L. Strong,et al.  Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. , 1992, American journal of human genetics.

[41]  E. Gritz,et al.  Psychological functioning of daughters of breast cancer patients. Part II: Characterizing the distressed daughter of the breast cancer patient. , 1992, Psychosomatics.